Head-To-Head Comparison: AstraZeneca (NYSE:AZN) and Concordia International (CXRX)

Concordia International (NASDAQ: CXRX) and AstraZeneca (NYSE:AZN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Insider & Institutional Ownership

8.6% of Concordia International shares are held by institutional investors. Comparatively, 14.8% of AstraZeneca shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Concordia International and AstraZeneca’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International -282.00% N/A -0.07%
AstraZeneca 13.36% 34.74% 8.52%

Volatility & Risk

Concordia International has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.


AstraZeneca pays an annual dividend of $1.37 per share and has a dividend yield of 4.0%. Concordia International does not pay a dividend. AstraZeneca pays out 116.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Concordia International and AstraZeneca, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International 1 0 0 0 1.00
AstraZeneca 1 6 12 0 2.58

AstraZeneca has a consensus price target of $38.00, suggesting a potential upside of 10.56%. Given AstraZeneca’s stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Concordia International.

Earnings & Valuation

This table compares Concordia International and AstraZeneca’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Concordia International $816.16 million 0.04 -$1.32 billion ($35.54) -0.02
AstraZeneca $22.47 billion 3.88 $3.00 billion $1.18 29.13

AstraZeneca has higher revenue and earnings than Concordia International. Concordia International is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.


AstraZeneca beats Concordia International on 13 of the 15 factors compared between the two stocks.

About Concordia International

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply